Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label study of KH631 ophthalmic injection in neovascular age-related macular degeneration
CTR20223382Phase 2Active
- Sponsor
- Chengdu Hongji Biotech
- Start
- Apr 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of KH631 in exudative macular degeneration, sponsored by Chengdu Hongji Biotech. Started Apr 2023; status: active.
02
Drugs
KH631
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20223382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223382.